title: Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT.
abstract: We studied GVHD after donor lymphocyte infusion (DLI) in 328 patients with relapsed CML between 1991 and 2004 . A total of 122 patients (38%) developed some form of GVHD. We analyzed GVHD by clinical presentation (acute or chronic GVHD) and onset time after the first DLI (early (< or =45 days) or late (>45 days)). There was a significant overlap between onset time and clinical presentation. Some form of GVHD occurred at a median of 104 days, acute GVHD at 45 days and chronic GVHD at 181 days after DLI. The clinical presentation was acute GVHD in 71 patients, of whom 31 subsequently developed chronic GVHD subsequently. De novo chronic GVHD was seen in 51 patients. OS for all patients was 69% (95% confidence interval (CI) 63-75) at 5 years, DLI-related mortality was 11% (95% CI 8-15) and disease-related mortality was 20% (95% CI 16-25). Risk factors for developing GVHD after DLI were T-cell dose at first DLI, the time interval from transplant to DLI and donor type. In time-dependent multivariate analysis, GVHD after DLI was associated with a risk of death of 2.3-fold compared with patients without GVHD. Clinical presentation as acute GVHD and early onset GVHD were associated with increased mortality.
authors.affiliation: Division of Hematology, Department of Internal Medicine, University Hospital, Geneva, Switzerland. yves.chalandon@hcuge.ch
authors.forename: Y
authors.initials: Y
authors.lastname: Chalandon
authors.forename: J R
authors.initials: JR
authors.lastname: Passweg
authors.forename: C
authors.initials: C
authors.lastname: Schmid
authors.forename: E
authors.initials: E
authors.lastname: Olavarria
authors.forename: F
authors.initials: F
authors.lastname: Dazzi
authors.forename: M P
authors.initials: MP
authors.lastname: Simula
authors.forename: P
authors.initials: P
authors.lastname: Ljungman
authors.forename: A
authors.initials: A
authors.lastname: Schattenberg
authors.forename: T
authors.initials: T
authors.lastname: de Witte
authors.forename: S
authors.initials: S
authors.lastname: Lenhoff
authors.forename: P
authors.initials: P
authors.lastname: Jacobs
authors.forename: L
authors.initials: L
authors.lastname: Volin
authors.forename: S
authors.initials: S
authors.lastname: Iacobelli
authors.forename: J
authors.initials: J
authors.lastname: Finke
authors.forename: D
authors.initials: D
authors.lastname: Niederwieser
authors.forename: C
authors.initials: C
authors.lastname: Guglielmi
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology* / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000628:therapy*; D017710:Lymphocyte Transfusion / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D012008:Recurrence; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult